Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

121. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD (...) , Chelladurai Y, Robinson KA CRD summary The authors concluded that lower-intensity statins combined with bile acid sequestrant or ezetimibe may be an alternative to higher-intensity statin monotherapy for high-risk statin-intolerant patients or those with a low response to statins; a cautious approach in practice was recommended. The authors' conclusion reflected the evidence presented and is likely to be reliable. Authors' objectives To evaluate the effectiveness of lower intensity statin combination

DARE.2014

123. Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients

Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients Statins do not improve cardiovascular outcomes for dialysis patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins do not improve cardiovascular outcomes for dialysis patients Article Text Therapeutics Systematic review and meta-analysis Statins do not improve cardiovascular outcomes for dialysis patients Ali Olyaei Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Palmer SC , Navaneethan SD

Evidence-Based Medicine (Requires free registration)2014

124. Diagnosis, prevention, and management of statin adverse effects and intolerance

Diagnosis, prevention, and management of statin adverse effects and intolerance DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

CMA Infobase (Canada)2014

125. Statins benefits and risks

Statins benefits and risks Statins: benefits and risks Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Statins: benefits and risks From: Therapeutic area: Statins (HMG-CoA reductase inhibitors) are widely used medicines for patients with lipid disorders and in the primary and secondary prevention of heart attack and stroke. Article date: May 2014 The statins currently available in the UK are simvastatin, atorvastatin, pravastatin, fluvastatin, and rosuvastatin (...) . Evidence from large clinical trials shows that statins can reduce heart attacks and the need for bypass surgery, and can save lives in certain patient groups. Meta-analysis of randomised trial data shows that if patients with a 10-year cardiovascular risk of at least 20% take statins for 5 years, it would prevent at least 450 heart attacks, strokes, or vascular deaths per 10,000 treated patients. The importance of statin safety data from clinical studies and clinical practice Large clinical trials also

MHRA Drug Safety Update2014

126. Cohort study: High-potency statins are associated with increased hospitalisations with acute kidney injury

Cohort study: High-potency statins are associated with increased hospitalisations with acute kidney injury High-potency statins are associated with increased hospitalisations with acute kidney injury | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-potency statins are associated with increased hospitalisations with acute kidney injury Article Text Aetiology Cohort study High-potency statins are associated with increased hospitalisations with acute kidney injury Daniel O Keys , Charles L Edelstein Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2014

127. Cohort study: Statin potency associated with incident diabetes in a real-world evaluation

Cohort study: Statin potency associated with incident diabetes in a real-world evaluation Statin potency associated with incident diabetes in a real-world evaluation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statin potency associated with incident diabetes in a real-world evaluation Article Text Aetiology Cohort study Statin potency associated with incident diabetes in a real-world evaluation Dylan L Steen , Deepak L Bhatt Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Carter AA , Gomes T , Camacho

Evidence-Based Medicine (Requires free registration)2014

128. Statins

Statins USE OF STATINS IN PREGNANCY 0344 892 0909 USE OF STATINS IN PREGNANCY (Date of issue: March 2017 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin) are a class of HMG-CoA reductase inhibitors used to lower (...) cholesterol. They act by inhibiting the conversion of HMG-CoA to mevalonate which is a rate-limiting step in the production of cholesterol in the liver. Statins may be indicated, as an adjunct to diet, for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia when non-pharmacological treatments (e.g. diet, exercise, weight reduction) are inadequate, or for reduction of cardiovascular morbidity and mortality in manifest atherosclerotic cardiovascular disease or diabetes

UK Teratology Information Service2014

129. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. 24825642 2014 05 14 2014 05 26 2016 10 17 1538-3598 311 18 2014 May 14 JAMA JAMA Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. 1870-82 10.1001/jama.2014.4030 In phase 2 studies (...) , evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries. Patients (n = 2067) were randomized to 1

JAMA2014

130. Observational study: New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment

Observational study: New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment Article Text Practice guideline Observational study New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment Vera Bittner Statistics from

Evidence-Based Medicine (Requires free registration)2014

131. IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

RxFiles2014

132. Statins and cognitive function: a systematic review

Statins and cognitive function: a systematic review Statins and cognitive function: a systematic review Statins and cognitive function: a systematic review Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM CRD summary This review concluded that published data did not suggest an adverse effect of statins on cognition but the strength of available evidence was limited, particularly with regard to high-dose statins. The authors highlighted (...) some limitations in their review. The authors' cautious conclusions reflect the evidence presented and their recommendation for further research seems appropriate. Authors' objectives To examine the association between statin therapy and cognitive function. Searching PubMed, EMBASE and The Cochrane Library were searched from inception through October 2012 for studies published in English. Bibliographies of included studies were scanned. US Food and Drug Administration (FDA) databases were searched

DARE.2013

133. Are statins effective for primary prevention in people with low cardiovascular risk?

Are statins effective for primary prevention in people with low cardiovascular risk? Are statins effective for primary prevention in people with low cardiovascular risk? » Morsels of Evidence Search Evidence based medicine for general practitioners « » Nov 08 Are statins effective for primary prevention in people with low cardiovascular risk? Categories: , by Journal reference: Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B (...) , Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011; 183(16): E1189-E1202 Link: Published: 24 October 2011 Evidence cookie says… Statins appear to have a (small) cardiovascular benefit, even in individuals at low CVD risk. The clinical meaningfulness of this benefit needs to be considered in the context of side-effects, opportunity costs, and patient preferences. Clinical scenario John, a well 52-year old business

Morsels of Evidence2013

134. Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial.

Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. IMPORTANCE: Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality. OBJECTIVE: To determine whether statin therapy can decrease day-28 mortality in patients with VAP. DESIGN (...) ventilation and Sequential Organ Failure Assessment (SOFA) scores on days 3, 7, and 14. RESULTS: The study was stopped for futility at the first scheduled interim analysis after enrollment of 300 patients, of whom all but 7% in the simvastatin group and 11% in the placebo group were naive to statin therapy at ICU admission. Day-28 mortality was not lower in the simvastatin group (21.2% [95% CI, 15.4% to 28.6%) than in the placebo group (15.2% [95% CI, 10.2% to 22.1%]; P = .10; hazard ratio, 1.45 [95% CI, 0.83

JAMA2013

135. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular (...) Diagnostics. Bibliographic details McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard CJ, Cobbe SM, Ford I. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal 2014; 35(5): 290-298 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Cardiovascular Diseases /economics /prevention & Cost-Benefit Analysis; Health Resources

NHS Economic Evaluation Database.2013

136. Is it safe to use statins in a patient with hepatitis C virus (HCV) infection?

Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is it safe to use statins in a patient with hepatitis C virus (HCV) infection? View/ Open Date 2013-04 Format (...) Metadata Abstract Treatment with statins appears safe in patients with compensated chronic HCV infection (SOR: C, disease-oriented outcomes). No data are available on the safe use of statins in patients with acute HCV infection. URI Part of Part of Citation Evidence Based Practice 16(4): 12. Collections hosted by hosted by

Evidence Based Practice 2013

137. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study 23839541 2014 02 03 2014 09 26 2016 10 19 1522-9645 35 5 2014 Feb European heart journal Eur. Heart J. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. 290-8 10.1093/eurheartj/eht232 To assess (...) the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). Six thousand five hundred and ninety-five participants aged 45-54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

138. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials

Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Fauchier L, Clementy N, Babuty D CRD summary This review concluded that statins reduced the risk of atrial fibrillation (...) in patients with sinus rhythm; the greatest benefit was in prevention of postoperative atrial fibrillation and secondary prevention of atrial fibrillation. Given the variability across studies, limitations of the evidence available, and lack of reporting of the review process, reliability of the review's conclusions is uncertain. Authors' objectives To investigate whether statins can prevent atrial fibrillation. Searching MEDLINE and EMBASE were searched for studies published in English in peer-reviewed

DARE.2013

139. Statins and the risk of interstitial lung disease: a cohort study

Statins and the risk of interstitial lung disease: a cohort study 23299962 2013 03 08 2013 07 08 2013 03 08 1468-3296 68 4 2013 Apr Thorax Thorax Statins and the risk of interstitial lung disease: a cohort study. 361-4 10.1136/thoraxjnl-2012-201823 Case reports have suggested that the use of statins may be associated with an increase in the risk of interstitial lung disease (ILD). Within a large cohort of users of respiratory medications identified in the Quebec health administrative databases (...) during 1990-2005, we carried out a nested case-control analysis of the relationship between statins and the risk of ILD as defined by specialist visits or hospitalisations. The cohort included over 1.4 million patients, of which 6665 possible or probable cases of ILD were identified during follow-up. These were compared with 26 660 controls matched for age, gender and calendar time. After adjustment for confounders and comorbid conditions, there was no association between current use of statins and

EvidenceUpdates2013

140. High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect

High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect 23674398 2013 06 26 2013 09 25 2015 11 19 1524-4539 127 25 2013 Jun 25 Circulation Circulation High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. 2485-93 10.1161/CIRCULATIONAHA.112.000712 Clinicians need to identify coronary (...) artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute risk for myocardial infarction, stroke, coronary death, or cardiac resuscitation. Based on data from the Treating to New Targets trial (TNT; n=10 001), a Cox proportional hazards model was developed comprising 13 easy

EvidenceUpdates2013